Navigation Links
Thalidomide Improves Outcomes for Older Myeloma Patients

Adding the drug to standard chemo boosted survival, study found

FRIDAY, Oct. 5 (HealthDay News) -- Elderly patients with multiple myeloma live longer when thalidomide is added to standard combination chemotherapy treatment, a new study finds.

The finding could be the first real treatment advance for these types of patients in decades, the researchers said.

Standard chemotherapy for elderly patients involves two drugs, melphalan plus prednisone, explained a French team who are publishing their findings in this week's issue of The Lancet medical journal.

The study included 447 previously untreated patients, ages 65 to 75, divided into three groups: 196 received melphalan and prednisone (MP); 125 received MP plus thalidomide (MPT); and 126 received reduced-intensity stem cell transplantation using melphalan (MEL100).

Median survival times were: 33.2 months in the MP group; 51.6 months in the MPT group; and 38.8 in the MEL100 group.

MPT patients were 41 percent less likely to die than MP patients and 31 percent less likely to die than MEL100 patients.

"Our study has shown that the addition of thalidomide to standard melphalan and prednisone significantly extended survival for elderly patients with previously untreated multiple myeloma," wrote a team led by Dr. Thierry Facon, of the Centre Hospitalier Universitaire de Lille. "We noted that the MPT regimen was better than the MP regimen in terms of response, including complete response, overall survival, and progression-free survival."

The researchers concluded that the results "provide strong evidence to suggest that the MPT combination, should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma. After 40 years of unsuccessful attempts to find a more effective treatment than the standard MP, the MPT combination opens an era of progress for elderly patients with the disease."

Two experts who weren't involved in the study agree. In an accompanying Lancet Comment, Dr. Antonio Palumbo and Dr. Mario Boccadoro wrote that "we now have extensive evidence to support the introduction of MPT as the standard of care for elderly patients with multiple myeloma."

More information

The American Cancer Society outlines treatment options for multiple myeloma.

-- Robert Preidt

SOURCE: The Lancet, news release, Oct. 5, 2007

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Thalidomide may stage a comeback
2. Thalidomide is the new approved drug for treating multiple cancers
3. Thalidomide for Tumor Treatment
4. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
5. Collagen improves voice quality in Parkinsonism
6. Breakfast improves memory
7. A new hearing device improves hearing
8. Hormone replacement therapy improves sexual function
9. New therapy improves quality of life for cancer
10. Adding contrast improves ultrasounds ability to detect prostate cancer
11. Switching drugs regularly improves HIV treatment
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: